There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Instil Bio (TIL – Research Report), Evolus (EOLS – Research Report) and 4D Molecular Therapeutics (FDMT – Research Report) with bullish sentiments.
Instil Bio (TIL)
Robert W. Baird analyst Jack Allen assigned a Buy rating to Instil Bio on January 18 and set a price target of $54.00. The company’s shares closed last Monday at $10.60.
According to TipRanks.com, Allen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Instil Bio with a $36.00 average price target, a 271.5% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Evolus (EOLS)
In a report issued on January 17, Marc Goodman from Leerink Partners maintained a Buy rating on Evolus, with a price target of $25.00. The company’s shares closed last Monday at $12.11, close to its 52-week high of $12.81.
According to TipRanks.com, Goodman is a 4-star analyst with an average return of
Evolus has an analyst consensus of Strong Buy, with a price target consensus of $23.40, which is a 95.0% upside from current levels. In a report issued on January 3, Stifel Nicolaus also maintained a Buy rating on the stock with a $23.00 price target.
4D Molecular Therapeutics (FDMT)
In a report issued on January 18, Kostas Biliouris from BMO Capital reiterated a Buy rating on 4D Molecular Therapeutics, with a price target of $50.00. The company’s shares closed last Monday at $17.59.
According to TipRanks.com, Biliouris is a 2-star analyst with an average return of
4D Molecular Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TIL:
